Abstract: Provided herein are chimeric antigen receptors (CARs) with binding specificity for CD123. Nucleic acids, expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of a hematopoietic malignancy or premalignancy characterized by the expression of CD123, e.g., leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Abstract: Provided herein are IL-2 reporter systems comprising nucleic acid constructs comprising a nucleotide sequence encoding a reporter molecule operably linked to a minimal nuclear factor of activated T cells (NFAT)-responsive promoter. Also provided herein are vectors, cells, and cell lines comprising such nucleic acids. Also provided herein are methods of making and using such cells, for example to measure the ability of a chimeric antigen receptor (CAR) to induce nuclear factor of activated T cells (NFAT)-signaling in a cell.

Abstract: According to one aspect, a vehicle safety system includes an actuatable controlled restraint (ACR) comprising a seatbelt for restraining a vehicle occupant. The ACR is actuatable to control payout and retraction of the seatbelt. The system also includes a controller configured to determine operating conditions of the vehicle and to control the actuation of the ACR in response to the determined operating conditions of the vehicle. The ACR has a normal restraint condition and an enhanced restraint condition, the controller being configured to actuate the ACR from the normal restraint condition to the enhanced restraint condition in response to determining abnormal driving conditions of the vehicle.

Abstract: The disclosure is directed to methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors, where the cells are mobilized lymphocytes.

Abstract: Provided are chimeric antigen receptors (CARs) with binding specificity for CD33. Nucleic acids, vectors, host cells, populations of cells expressing the CARs, and pharmaceutical compositions relating to the CARs are also disclosed, and methods including the treatment of CD33-related diseases, in particular, leukemias such as acute myeloid leukemia (AML).

Abstract: The present disclosure includes antibodies that specifically CD33, as well as methods of making and using such antibodies.

Abstract: Aspects of this disclosure provide nucleic acid constructs A nucleic acid construct, comprising a first expression cassette comprising a nucleic acid encoding a tetracycline-responsive transactivator under the control of a cell type-specific promoter; and a second expression cassette comprising a nucleic acid encoding a transgene, for example, a chimeric antigen receptor (CAR), under the control of a tetracycline-responsive promoter.

Abstract: The present disclosure concerns methods of treating cancer with neoantigenic peptides such that durable clinical benefits are obtained, and compositions and methods for determining whether DCB can be predicted or assessed for a patient to be treated with a therapeutic comprising neoantigen.